New anabolic agents in the treatment of osteoporosis

Journal of Endocrinology, Metabolism and Diabetes of South Africa

Volumn 8, Issue 2, 2003, Pages 44-46

  Hough, Stephen ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ANABOLIC AGENT; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; CALCITONIN; CALCIUM; ESTROGEN; FLUORIDE; FLUORIDE SODIUM; GLUCOCORTICOID; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; STRONTIUM; VITAMIN D;

APOPTOSIS; BONE DENSITY; BONE FRAGILITY; BONE MASS; BONE MINERAL; BONE TUMOR; BONE TURNOVER; CELL PROLIFERATION; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; COST EFFECTIVENESS ANALYSIS; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; LEG CRAMP; NAUSEA; NEPHROLITHIASIS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA;

EID: 0242331251     PISSN: 16089677     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (27)

1. Cummings SR, Melton LJ III. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-1767.
2. Kanis JA. Osteoporosis. London: Blackwell, 1997.
3. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002, 359: 2018-2026.
4. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2002, 289: 1508-1514.
5. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322: 802-809.
6. Pak CY, Zerwekh JE, Antich PP, et al. Slow-release sodium fluoride in osteoporosis. J Bone Miner Res 1996; 11: 561-564.
7. Gutteridge DH, Gutteridge DH, Stewart GO, et al. A randomised trial of sodium fluoride and estrogen in post menopausal osteoporotic vertebral fractures. Osteoporosis Int 2002; 13(2): 158-170.
8. Ringe JD, Rovati LC. Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. Calcif Tissue Int 2001; 69: 252-255.
9. Bauer DC, Rosen CJ, Cauley J, et al. Low serum IGF-1 but not IGFBP-3 predicts hip and spine fracture: the study of osteoporotic fracture. J Bone Miner Res 1998; 23: S561.
10. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1946-1949.
11. Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S. Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 2001; 21: 1636-1641.
12. Van Staa TP, Wegman S, De Vries F, et al. Use of statins and risk of fractures. JAMA 2001; 285: 1850-1855.
13. Meunier PJ, Roux C, Ortolani S, et al. Strontium ranelate reduces the vertebral fracture risk in women with postmenopausal osteoporosis. Osteoporosis Int 2002; 13: Suppl 1, 45.
14. Tam CS, Heersche JN, Murray TM, Parsons JA. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 1982; 10: 506-512.
15. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997; 350: 550-555.
16. Hirano T, Burr DB, Turner CH, et al. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 1999; 14: 536-545.
17. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441.
18. Body JJ, Gaich GA, Scheele WH, et al. A randomised double-blind trial to compare the efficacy of teriparatide (recombinant human parathyroid hormone 1-34) with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87: 4528-4535.
19. Rubin MR, Bilezikian JP. New anabolic therapies in osteoporosis. Endocrinol Metab Clin N Am 2003; 32: 285-307.
20. Roe E, Sanchez S, Del Puerto G, et al. Parathyroid hormone (hPTH1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis: results from a placebo-controlled randomised trial. J Bone Miner Res 1999; 14: S137.
21. Kurland ES, Cosman F, McMahon D, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000; 85: 3069-3076.
22. Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: results of a randomised controlled clinical trial. J Clin Invest 1998; 102: 1627-1633.
23. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001; 16: 1846-1853.
24. Sato M, Westmore M, Clendenon J, et al. Three-dimensional modeling of the effects of parathyroid hormone on bone distrubution in lumbar vertebrae of ovariectomized cynomalgus macaques. Osteoporosis Int 2000; 11: 871-880.
25. Orwoll E, Sheele WH, Clancy AD, et al. Recombinant human parathyroid hormone (1-34) therapy reduces the incidence of moderate/severe vertebral fractures in men with low bone density. J Bone Miner Res 2001; 16: 1104.
26. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002; 30: 312-321.
27. Tashjian AH jr, Chabner BA. Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 2002; 17: 1152-1161.